Side-by-side comparison of AI visibility scores, market position, and capabilities
Encapsulate Bio develops tumor-on-a-chip microfluidic platforms that test patient-derived tumor samples against cancer therapies to guide personalized treatment selection; early-stage biotech focused on ex vivo drug sensitivity testing for oncology.
Encapsulate Bio is an early-stage biotechnology company focused on advancing personalized cancer medicine through its proprietary tumor-on-a-chip platform. The technology creates miniaturized, microfluidic three-dimensional models of patient-derived tumors — capturing the complex cellular architecture and microenvironment of real cancer tissue — and exposes these microtumors to panels of therapeutic agents to generate rapid, clinically relevant drug sensitivity data. The goal is to give oncologists predictive, patient-specific treatment guidance before committing to a full course of chemotherapy or targeted therapy, reducing the trial-and-error approach that currently characterizes much of oncology treatment selection.
Saluda Medical is the pioneer of closed-loop spinal cord stimulation (SCS); FDA-approved Evoke SCS system with real-time neural feedback; raised $100M in Jan 2025; received FDA clearance for automated EVA programming platform.
Saluda Medical is a commercial-stage medical device company that has pioneered closed-loop neuromodulation therapy for chronic pain management. Headquartered in Macquarie Park, Australia (with US operations in Marlborough, Massachusetts), Saluda''s flagship product is the Evoke Spinal Cord Stimulation (SCS) System — the world''s first SCS system that senses and measures neural responses to stimulation (evoked compound action potentials, or ECAPs) and automatically adjusts therapy in real time based on each patient''s neurophysiological feedback. This closed-loop approach provides more precise, consistent pain relief compared to conventional open-loop SCS systems.
Encapsulate Bio vs
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.